Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Time to Sell?

Zealand Pharma A/S (OTCMKTS:ZLDPF) gapped down before the market opened on Tuesday . The stock had previously closed at $46.3750, but opened at $43.1050. Zealand Pharma A/S shares last traded at $43.1050, with a volume of 103 shares traded.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on ZLDPF shares. Barclays lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 8th. Zacks Research upgraded shares of Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a report on Friday, September 11th. Wells Fargo & Company restated an “overweight” rating on shares of Zealand Pharma A/S in a research note on Thursday, August 13th. Wolfe Research downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Finally, Berenberg Bank downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, Zealand Pharma A/S presently has an average rating of “Hold”.

Zealand Pharma A/S Price Performance

The company has a fifty day simple moving average of $47.25 and a two-hundred day simple moving average of $46.51. The stock has a market capitalization of $3.08 billion, a price-to-earnings ratio of 7.15 and a beta of 0.89. The company has a debt-to-equity ratio of 0.02, a quick ratio of 37.17 and a current ratio of 37.17.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing peptide-based medicines. The company’s research programs address serious and underserved conditions, particularly metabolic diseases, gastrointestinal disorders and rare diseases. Zealand combines proprietary peptide technologies with drug-development expertise to create therapies designed to improve treatment outcomes and patient convenience.

Zealand’s commercial portfolio includes Zegalogue (dasiglucagon), an injectable treatment for severe hypoglycemia in people with diabetes.